GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (OSTO:SPAGO) » Definitions » Cyclically Adjusted PS Ratio

Spago Nanomedical AB (OSTO:SPAGO) Cyclically Adjusted PS Ratio : 15.30 (As of Jun. 19, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Spago Nanomedical AB Cyclically Adjusted PS Ratio?

As of today (2024-06-19), Spago Nanomedical AB's current share price is kr0.306. Spago Nanomedical AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr0.02. Spago Nanomedical AB's Cyclically Adjusted PS Ratio for today is 15.30.

The historical rank and industry rank for Spago Nanomedical AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

OSTO:SPAGO' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 11.95   Med: 25.6   Max: 154.28
Current: 19.83

During the past years, Spago Nanomedical AB's highest Cyclically Adjusted PS Ratio was 154.28. The lowest was 11.95. And the median was 25.60.

OSTO:SPAGO's Cyclically Adjusted PS Ratio is ranked worse than
82.57% of 505 companies
in the Biotechnology industry
Industry Median: 5.29 vs OSTO:SPAGO: 19.83

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Spago Nanomedical AB's adjusted revenue per share data for the three months ended in Mar. 2024 was kr0.001. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr0.02 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Spago Nanomedical AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Spago Nanomedical AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB Cyclically Adjusted PS Ratio Chart

Spago Nanomedical AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 111.58 18.67 20.51

Spago Nanomedical AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.28 37.06 20.84 20.51 18.79

Competitive Comparison of Spago Nanomedical AB's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Spago Nanomedical AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spago Nanomedical AB's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Spago Nanomedical AB's Cyclically Adjusted PS Ratio falls into.



Spago Nanomedical AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Spago Nanomedical AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.306/0.02
=15.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spago Nanomedical AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Spago Nanomedical AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.001/132.2054*132.2054
=0.001

Current CPI (Mar. 2024) = 132.2054.

Spago Nanomedical AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.005 100.432 0.007
201409 0.002 100.161 0.003
201412 0.000 100.225 0.000
201503 0.000 99.950 0.000
201506 0.000 99.995 0.000
201509 0.000 100.228 0.000
201512 0.000 100.276 0.000
201603 0.002 100.751 0.003
201606 0.000 101.019 0.000
201609 0.004 101.138 0.005
201612 0.000 102.022 0.000
201703 0.000 102.022 0.000
201706 0.000 102.752 0.000
201709 0.000 103.279 0.000
201712 0.003 103.793 0.004
201803 0.000 103.962 0.000
201806 0.000 104.875 0.000
201809 0.000 105.679 0.000
201812 0.000 105.912 0.000
201903 0.000 105.886 0.000
201906 0.001 106.742 0.001
201909 0.000 107.214 0.000
201912 0.000 107.766 0.000
202003 0.004 106.563 0.005
202006 0.000 107.498 0.000
202009 0.002 107.635 0.002
202012 0.005 108.296 0.006
202103 0.003 108.360 0.004
202106 0.006 108.928 0.007
202109 0.004 110.338 0.005
202112 0.002 112.486 0.002
202203 0.005 114.825 0.006
202206 0.007 118.384 0.008
202209 0.005 122.296 0.005
202212 0.001 126.365 0.001
202303 0.001 127.042 0.001
202306 0.001 129.407 0.001
202309 0.003 130.224 0.003
202312 0.005 131.912 0.005
202403 0.001 132.205 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Spago Nanomedical AB  (OSTO:SPAGO) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Spago Nanomedical AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Spago Nanomedical AB (OSTO:SPAGO) Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through previous detection of tumors and metastases. The Tumorad products focuses on the development of a completely new form of radionuclide therapy for tumor selective radiation therapy of cancer. The company development projects are based on a platform of polymeric materials with varoious properties for precise diagnosis and treatment of life threatening and debilitating diseases.

Spago Nanomedical AB (OSTO:SPAGO) Headlines

No Headlines